Overview
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
Status:
Terminated
Terminated
Trial end date:
2008-12-01
2008-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and Statistical Manual (DSM - IV) with the first visits on days 1, 2, 4 or 5 and 7 ± 1.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AstraZenecaTreatments:
Quetiapine Fumarate
Risperidone
Criteria
Inclusion Criteria:- In the opinion of the Investigator, requirement for treatment for an acute episode of
schizophrenia, schizoaffective disorder or schizophreniformic psychosis (according to
DSM-IV diagnostic criteria), Positive and Negative Symptoms Scale (PANSS) ≥ 65, CGI ≥
4
Exclusion Criteria:
- Pregnancy or lactation
- In-patients/hospitalized > 7 days before enrollment
- Known intolerance or lack of response to quetiapine fumarate or risperidone, as judged
by the investigator